Luspatercept Eyes Treatment of Anemia in Low-Risk MDS Luspatercept Eyes Treatment of Anemia in Low-Risk MDS
Luspatercept, an investigational agent, shows promise in treating anemia in low-risk myelodysplastic syndromes based on a phase 2 study. Larger studies are underway.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
More News: Anemia | Cancer & Oncology | Eyes | Health | Hematology | Myelodysplastic Syndrome | Study